Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy

被引:32
|
作者
van de Donk, Pim P. [1 ]
Wind, Thijs T. [1 ]
Hooiveld-Noeken, Jahlisa S. [1 ]
van der Veen, Elly L. [1 ]
Glaudemans, Andor W. J. M. [2 ]
Diepstra, Arjan [3 ]
Jalving, Mathilde [1 ]
de Vries, Elisabeth G. E. [1 ]
de Vries, Erik F. J. [2 ]
Hospers, Geke A. P. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, POB 30-001, NL-9700 RB Groningen, Netherlands
[2] Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
关键词
Positron emission tomography; T cells; Immunotherapy; Interleulcin-2; Melanoma; NIVOLUMAB;
D O I
10.1007/s00259-021-05407-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into treatment efficacy. Activated tumor-infiltrating T cells express the high-affinity interleukin-2 receptor (IL-2R). Therefore, we performed a pilot study, using fluorine-18-labeled IL-2 ([F-18]FB-1L2 PET), to evaluate whether a treatment-induced immune response can be detected. Methods Patients with metastatic melanoma received similar to 200 MBq [F-18]FB-IL2 intravenously, followed by a PET/CT scan before and during immune checkpoint inhibitor therapy. [F-18]FB-IL2 uptake was measured as standardized uptake value in healthy tissues (SUVmean) and tumor lesions (SUVmax). Response to therapy was assessed using RECIST v1.1. Archival tumor tissues were used for immunohistochemical analyses of T cell infiltration. Results Baseline [F-18]FB-IL2 PET scans were performed in 13 patients. SUVmean at baseline was highest in the kidneys (14.2, IQR: 11.6-18.0) and liver (10.6, IQR: 8.6-13.4). In lymphoid tissues, uptake was highest in spleen (10.9, IQR: 8.8-12.4) and bone marrow (2.5, IQR: 2.1-3.0). SUVmax in tumor lesions (n = 41) at baseline was 1.9 (IQR: 1.7-2.3). In 11 patients, serial imaging was performed, three at week 6, seven at week 2, and one at week 4. Median [F-18]FB-IL2 tumor uptake decreased from 1.8 (IQR: 1.7-2.1) at baseline to 1.7 (IQR: 1.4-2.1) during treatment (p = 0.043). Changes in [F-18]FB-11.2 tumor uptake did not correlate with response. IL-2R expression in four archival tumor tissues was low and did not correlate with baseline [F-18]FB-IL2 uptake. No [F-18]FB-IL2-related side effects occurred. Conclusion PET imaging of the IL-2R, using [F-18]FB-IL2, is safe and feasible. In this small patient group, serial [F-18]FB-IL2-PEr imaging did not detect a treatment-related immune response.
引用
收藏
页码:4369 / 4376
页数:8
相关论文
共 50 条
  • [1] Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
    Pim P. van de Donk
    Thijs T. Wind
    Jahlisa S. Hooiveld-Noeken
    Elly L. van der Veen
    Andor W. J. M. Glaudemans
    Arjan Diepstra
    Mathilde Jalving
    Elisabeth G. E. de Vries
    Erik F. J. de Vries
    Geke A. P. Hospers
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 4369 - 4376
  • [2] LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy
    van de Donk, Pim P.
    Smit, Lotte M.
    van Sluis, Joyce
    Timens, Wim
    Brouwers, Adrienne H.
    Lub-de Hooge, Marjolijn N.
    Elias, Sjoerd G.
    Gietema, Jourik A.
    van Winkel, Claudia A.
    Wang, JuAn
    Giurleo, Jason
    Uldrick, Thomas
    Cheung, Hung Kam
    Jalving, Hilde
    Oosting, Sjoukje F.
    Knapen, Daan G.
    de Groot, Derk-Jan A.
    de Vries, Elisabeth G.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] INTERLEUKIN-2 THERAPY IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
    DORVAL, T
    FRIDMAN, WH
    MATHIOT, C
    SASTRE, X
    POUILLART, P
    BULLETIN DU CANCER, 1992, 79 (08) : 781 - 787
  • [4] Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic Melanoma
    Zaremba, A.
    Ferdinandus, J.
    Zimmer, L.
    Umutlu, L.
    Seifert, R.
    Barbato, F.
    Ugurel, S.
    Chorti, E.
    Gruenwald, V.
    Herrman, K.
    Schadendorf, D.
    Fendler, W. P.
    Livingstone, E.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 75 - 76
  • [5] INTERLEUKIN-2 THERAPY FOR METASTATIC UVEAL MELANOMA
    DORVAL, T
    FRIDMAN, WH
    MATHIOT, C
    POUILLART, P
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (12) : 2087 - 2087
  • [6] Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma
    Langan, Ewan A.
    Kuempers, Christiane
    Graetz, Victoria
    Perner, Sven
    Zillikens, Detlef
    Terheyden, Patrick
    DERMATOLOGIC THERAPY, 2019, 32 (03)
  • [7] Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients
    Cosgarea, I
    Zimmer, L.
    Weide, B.
    Gutzmer, R.
    Heinzerling, L.
    Weishaupt, C.
    Pfoehler, C.
    Gesierich, A.
    Herbst, R.
    Kaehler, K.
    Schlaak, M.
    Loquai, C.
    Utikal, J.
    Kaatz, M.
    Berking, C.
    Kreuter, A.
    Ulrich, J.
    Mohr, P.
    Dippel, E.
    Livingstone, E.
    Weichenthal, M.
    Schadendorf, D.
    Ugurel, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 16 - 17
  • [8] A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
    Mooradian, Meghan J.
    Reuben, Alexandre
    Prieto, Peter A.
    Hazar-Rethinam, Mehlika
    Frederick, Dennie T.
    Nadres, Brandon
    Piris, Adriano
    Juneja, Vikram
    Cooper, Zachary A.
    Sharpe, Arlene H.
    Corcoran, Ryan B.
    Flaherty, Keith T.
    Lawrence, Donald P.
    Wargo, Jennifer A.
    Sullivan, Ryan J.
    ONCOIMMUNOLOGY, 2018, 7 (05):
  • [9] Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma
    Fallick, ML
    McDermott, DF
    LaRock, D
    Long, JP
    Atkins, MB
    JOURNAL OF UROLOGY, 1997, 158 (05): : 1691 - 1695
  • [10] Interleukin-2 plus chemotherapy for patients with metastatic melanoma
    Paciucci, PA
    Ryder, JS
    Mandeli, JP
    Morris, JC
    Holland, JF
    MELANOMA RESEARCH, 2000, 10 (03) : 291 - 295